Skip to main content

Selected References

Selected References

  • Tillmanns, J.*, Kicuntod, J.*, Lösing, J., & Marschall, M. (2024), “Getting better” – is it a feasible strategy of broad pan-antiherpesviral drug targeting by using the nuclear egress-directed mechanism? Review, Int. J. Mol.. Sci 25: 2823, doi.org/10.3390/ijms25052823, PMID: 38474070 (*contributed equally).
  • Yu, D.H.*, Wagner, S.*, Schütz, M., Jeon, Y., Seo, M., Kim, J., Brückner, N., Kicuntod, J., Tillmanns, J., Wangen, C., Hahn, F., Kaufer, B.B., Neipel, N., Eickhoff, J., Klebl, B., Nam, K. & Marschall, M. (2024) An antiherpesviral host-directed strategy based on CDK7 covalently binding drugs: target-selective, picomolar-dose, cross-virus reactivity. Pharmaceutics pharmaceutics-2808137 (*contributed equally).
  • Schütz, M., Cordsmeier, A., Wangen, C., Horn, A.H.C., Wyler, E., Ensser, E., Sticht, H. & Marschall, M. (2023) The interactive complex between cytomegalovirus kinase vCDK/pUL97 and host factors CDK7–cyclin H determines individual patterns of transcription in infected cells. Int. J. Mol. Sci. 24, 17421, doi.org/10.3390/ijms242417421.
  • Wangen, C.*, Raithel, A.*, Tillmanns, J., Gege, C., Herrmann, A., Vitt, D., Kohlhof, H., Marschall, M. & Hahn, F. (2023). Validation of nuclear receptor RORγ isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels. Antiviral Res. 221:105769, doi: 10.1016/j.antiviral.2023.105769, PMID: 38056603 (*contributed equally).
  • Wild, M., Karner, D., Eickhoff, J., Wagner, S., Kicuntod, J., Chang, W., Barry, P., Jonjić, S., Lenac Roviš, T. & Marschall, M. (2023). Combined treatment with host-directed and anticytomegaloviral kinase inhibitors: mechanisms, synergisms and drug resistance barriers. Pharmaceutics 15: 2680, doi.org/10.3390/pharmaceutics15122680.
  • Schütz, M., Wangen, C., Sommerer, M., Kögler, M., Eickhoff, J., Degenhart, C., Klebl, B., Naing, Z., Egilmezer, E., Hamilton, S.T., Rawlinson, W.D., Sticht, H. & Marschall, M. (2023). Cytomegalovirus cyclin-dependent kinase ortholog vCDK/pUL97 undergoes regulatory interaction with human cyclin H and CDK7 to codetermine viral replication efficiency. Virus Res. 335: 199200, doi: 10.1016/j.virusres.2023.199200, PMID: 37591314.
  • Herrmann, L., Hahn, F., Grau, B.W., Wild, M., Niesar, A., Wangen, C., Kataev, E., Marschall, M.* & Tsogoeva S.B.* (2023). Autofluorescent artemisinin-benzimidazole hybrids via organo-click reaction: study of antiviral properties and mode of action in live cells. Chem. Eur. J. 2023, e202301194, doi.org/10.1002/chem.202301194 (*contributed equally).
  • Tillmanns, J., Häge, S., Borst, E.B., Wardin, J., Eickhoff, J., Klebl, B., Wagner, S., Wangen, C., Hahn, F., Socher, E. & Marschall, M. (2023). Assessment of covalently binding warhead compounds in the validation of the cytomegalovirus nuclear egress complex as an antiviral target. Cells 12: 1162, doi.org/10.3390/cells12081162, PMID: 37190072.
  • Kicuntod, J., Häge, S., Lösing, J., Kopar, S., Muller, Y.A. & Marschall, M. (2023). An antiviral targeting strategy based on the inducible interference with cytomegalovirus nuclear egress complex. Antiviral Res. 105557. doi: 10.1016/j.antiviral.2023.105557, PMID: 36796541.
  • Hahn, F., Wangen, C., Häge, S., Herrmann, L., Herrmann, A., Tsogoeva, S.B. & Marschall, M. (2023). The trimeric artesunate analog TF27, a broadly acting anti-infective model drug, exerts pronounced anti-SARS-CoV-2 activity spanning variants and host cell types. Pharmaceutics 15: 115, doi.org/10.3390/pharmaceutics15010115, PMID: 36678744.
  • Lösing, J., Häge, S., Schütz, M., Wagner, S., Wardin, J., Sticht, H. & Marschall, M. (2022). 'Shared-hook' and 'changed-hook' binding activities of herpesviral core nuclear egress complexes identified by random mutagenesis. Cells 11: 4030, doi: 10.3390/cells11244030, PMID: 36552794.
  • Alkhashrom, S.*, Kicuntod, J.*, Stillger, K., Lützenburg, T., Anzenhofer, C., Neundorf, I., Marschall, M. & Eichler, J. (2022). A peptide inhibitor of the human cytomegalovirus core nuclear egress complex. Pharmaceuticals 15: 1040, PMID: 36145260 (*contributed equally).
  • Schütz, M., Müller, R., Socher, E., Wangen, C., Full, F., Wyler, E., Wong, D., Scherer, M., Stamminger, T., Chou, S., Rawlinson, W.D., Hamilton, S.T., Sticht, H. & Marschall, M. (2022). Highly conserved interaction profiles between clinically relevant mutants of the cytomegalovirus CDK-like kinase pUL97 and human cyclins: functional significance of cyclin H. Int. J. Mol. Sci. 23: 11814, PMID: 36233116. 
  • Häge, S. & Marschall. M. (2022) 'Come together' – the regulatory interaction of herpesviral nuclear egress proteins comprises both essential and accessory functions. REVIEW, Cells 11: 1837, doi: 10.3390/cells11111837, PMID: 35681532.
  • Kicuntod, J., Häge, S., Hahn, F., Sticht, H. & Marschall, M. (2022). The oligomeric assemblies of cytomegalovirus core nuclear egress proteins are associated with host kinases and show sensitivity to antiviral kinase inhibitors. Viruses 14: 1021, doi: 10.3390/v14051021, PMID: 35632762.
  • Wild, M., Hahn, F., Brückner, N., Schütz, M., Wangen, C., Wagner, S., Sommerer, M., Strobl, S. & Marschall, M. (2022). Cyclin-dependent kinases (CDKs) and the human cytomegalovirus-encoded CDK ortholog pUL97 represent highly attractive targets for synergistic drug combinations. Int. J. Mol. Sci. 23: 2493 doi: 10.3390/ijms23052493, PMID: 35269635.
  • Schweininger, J.*, Kriegel, M.*, Häge, S., Conrad, M., Alkhashrom, S., Lösing, J., Weiler, S., Tillmanns, J., Egerer-Sieber, C., Decker, A., Lenac Roviš, T., Eichler, J., Sticht, H., Marschall, M. & Muller, Y. A. (2022). The crystal structure of the varicella-zoster Orf24-Orf27 nuclear egress complex spotlights multiple determinants of herpesvirus subfamily specificity. J. Biol. Chem. 101625, doi: 10.1016/j.jbc.2022.101625, PMID: 35074430 (*contributed equally).
  • Hahn, F., Hamilton, S.T., Wangen, C., Wild, M., Kicuntod, J., Brückner, N., Follett, J.E.L., Herrmann, L., Kheimar, A., Kaufer, B.B., Rawlinson, W.D., Tsogoeva, S.B. & Marschall, M. (2021). Development of a PROTAC-based targeting strategy provides a mechanistically unique mode of anti-cytomegalovirus activity. Int. J. Mol. Sci., 22: 12858, PMID: 34884662.
  • Häge, S., Büscher, N., Pakulska, V., Hahn, F., Adrait, A., Krauter, S., Borst, E.M., Schlötzer-Schrehardt, U., Couté, Y., Plachter, B. & Marschall, M. (2021). The complex regulatory role of cytomegalovirus nuclear egress protein pUL50 in the production of infectious virus. Cells 10: 3119, PMID: 34831342.
  • Hahn, F., Häge, S., Herrmann, A., Wangen, C., Jungnickl, D., Tillmanns, J., Müller, R., Fraedrich, K., Überla, K., Kohlhof, H., Ensser, A. & Marschall, M. (2021). Methodological development of a multi-readout assay for the assessment of antiviral drugs against SARS-CoV-2. Pathogens 10: 1076, PMID: 34578109.
  • Schütz, M., Steingruber, M., Socher, E., Müller, R., Wagner, S., Kögel, M., Sticht, H. & Marschall, M. (2021). Functional relevance of the interaction between human cyclins and the cytomegalovirus-encoded CDK-like protein kinase pUL97. Viruses 13: 1248, doi.org/10.3390/v13071248, PMID: 34198986.
  • Kicuntod, J., Alkhashrom, S., Häge, S., Diewald, B., Müller, R., Hahn, F., Lischka, P., Sticht, H., Eichler, J. & Marschall, M. (2021). Properties of oligomeric interaction of the cytomegalovirus core nuclear egress complex (NEC) and its sensitivity to an NEC inhibitory small molecule. Viruses 12: 683, PMID: 33799898.
  • Häge, S., Sonntag, E., Svrlanska, A., Borst, E.M., Stilp, A.C., Horsch, D., Müller, R., Kropff, B., Milbradt, J., Stamminger, T., Schlötzer-Schrehardt, U. & Marschall, M. (2021). Phenotypical characterization of the nuclear egress of recombinant cytomegaloviruses reveals defective replication upon ORF-UL50 deletion but not pUL50 phosphosite mutation. Viruses 13: 165, doi: 10.3390/v13020165, PMID: 33499341.
  • Wild, M., Kicuntod, J., Seyler, L., Wangen, C., Bertzbach, L.D., Conradie, A.M., Kaufer, B.B., Wagner, S., Michel, D., Eickhoff, J., Tsogoeva, S.B., Bäuerle, T., Hahn, F., Marschall, M. (2021). Combinatorial drug treatments reveal promising anticytomegaloviral profiles for clinically relevant pharmaceutical kinase inhibitors (PKIs). Int. J. Mol. Sci. 22: E575, doi: 10.3390/ijms22020575, PMID: 33430060.
  • Hahn, F., Wangen, C., Häge, S., Peter, A.S., Dobler, G., Hurst, B., Julander, J., Fuchs, J., Ruzsics, Z., Überla, K., Jäck, H.M., Ptak, R.G., Muehler, A., Gröppel, M., Vitt, D., Peelen, E., Kohlhof, H. & Marschall, M. (2020). IMU-838, a developmental DHODH inhibitor in phase II for autoimmune disease, shows anti-SARS-CoV-2 and broad-spectrum antiviral efficacy in vitro. Viruses 12, 1394, doi: 10.3390/v12121394, PMID: 33291455.
  • Hahn, F., Niesar, A., Wangen, C., Wild, M., Grau, B., Herrmann, L., Capci, A., Adrait, A., Couté, Y., Tsogoeva, S.B. & Marschall, M. (2020). Target verification of artesunate-related antiviral drugs: assessing the role of mitochondrial and regulatory proteins by click chemistry and fluorescence labeling. Antiviral Res. 104861, doi: 10.1016/j.antiviral.2020.104861, PMID: 32590041.
  • Häge, S., Horsch, D., Stilp, A.C., Kicuntod, J., Müller, R., Hamilton, S.T., Egilmezer, E., Rawlinson, W.D., Stamminger, T., Sonntag, E. & Marschall, M. (2020). A quantitative nuclear egress assay to investigate the nucleocytoplasmic capsid release of human cytomegalovirus. J. Virol. Methods 283: 113909, doi: 10.1016/j.jviromet.2020.113909, PMID: 32544419.
  • Couté, Y., Kraut, A., Zimmermann, C., Büscher, N., Hesse, A.M., Bruley, C., De Andrea, M., Wangen, C., Hahn, F., Marschall, M. & Plachter, B. (2020). Mass spectrometry-based characterization of the virion proteome, phosphoproteome, and associated kinase activity of human cytomegalovirus. REVIEW, Microorganisms 8: 820, doi: 10.3390/microorganisms8060820, PMID: 32486127.
  • Schütz, M., Thomas, M.*, Wangen, C., Wagner, S., Rauschert, L., Errerd, T., Kießling, M., Sticht, H., Milbradt, J.* & Marschall, M. (2020). The peptidyl-prolyl cis/trans isomerase Pin1 interacts with three early regulatory proteins of human cytomegalovirus. Virus Res. 285: 198023, doi: 10.1016/j.viruses.2020.198023, PMID: 32428517 (*contributed equally).
  • Wild, M., Bertzbach, L.D., Tannig, P., Wangen, C., Müller, R., Herrmann, L., Fröhlich, T., Tsogoeva, S.B., Kaufer, B.B., Marschall, M. & Hahn, F. (2020). The trimeric artesunate derivative TF27 exerts strong anti-cytomegaloviral efficacy: focus on prophylactic efficacy and oral treatment of immunocompetent mice. Antiviral Res. 178: 104788, doi: 10.1016/j.antiviral.2020.104788, PMID: 32251769.
  • Marschall, M., Häge, S.*, Conrad, M.*, Alkhashrom, S.*, Kicuntod, J., Schweininger, J., Kriegel, M., Lösing, J., Tillmanns, J., Neipel, F., Eichler, J., Muller, Y.A. & Sticht, H. (2020). Nuclear egress complexes of HCMV and other herpesviruses: solving the puzzle of sequence coevolution, conserved structures and subfamily-spanning binding properties. REVIEW, Viruses 12, 683, doi:10.3390/v12060683, PMID: 32599939 (*contributed equally).
  • Steingruber M. & Marschall, M. (2020). The cytomegalovirus protein kinase pUL97: host interactions, regulatory mechanisms and antiviral drug targeting. REVIEW, Microorganisms 8, 515, doi: 10.3390/microorganisms8040515, PMID: 32260430.
  • Muller, Y.A., Häge, S., Alkhashrom, S., Höllriegl, T., Weigert, S., Dolles, S., Hof, K., Walzer, S.A., Egerer-Sieber, C., Conrad, M., Holst, S., Lösing, J., Sonntag, E., Sticht, H., Eichler, J. & Marschall, M. (2020). High-resolution crystal structures of two prototypical β- and γ-herpesviral nuclear egress complexes unravel the determinants of subfamily specificity. J. Biol. Chem. pii: jbc.RA119.011546, doi: 10.1074/jbc.RA119.011546, PMID: 31980459.
  • Marschall, M., Strojan, H., Kiener, R., Wangen, C., Sonntag, E., Müller, R., Zeitträger, I., Wagner, S., Stamminger, T., Milbradt, J., Behrends, U., Körber, N., Bauer, T., Schrödel, S., Thirion, C., Wagner, R. & Hutterer, C. (2020). Differential upregulation of host cell protein kinases by the replication of -, - and -herpesviruses in human fibroblasts provides a signature of virus-specific signaling. J. Gen. Virol., doi: 10.1099/jgv.0.001370, PMID: 31958050.
  • Steingruber, M., Keller, L., Socher, E., Ferre, S., Hesse, A.M., Couté, Y., Hahn, F., Büscher, N., Plachter, B., Sticht, H. & Marschall, M. (2019). Cyclins B1, T1 and H differ in their molecular mode of interaction with cytomegalovirus protein kinase pUL97. J. Biol. Chem. 294: 6188-6203, PMID: 30782840.
  • Sonntag, E., Hahn, F., Bertzbach, L.D., Seyler, L., Wangen, C., Tannig, P., Grau, B., Baumann, M., Zent, E., Zischinsky, G., Eickhoff, J., Kaufer, B., Bäuerle, T., Tsogoeva, S. & Marschall, M. (2019). In vivo proof-of-concept for two experimental antiviral drugs, both directed to cellular targets, using a murine cytomegalovirus model. Antiviral Res. 161: 63-69, PMID: 30452929.
Öffnet Webseite der FAU - Friedrich Alexander Universität - Medizinische Fakultät Erlangen-Nürnberg
Öffnet PDF Zertifikat TÜV SÜD ISO 9001
Öffnet Webseite der Forschungsstiftung Medizin